• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Treatment of Nontuberculous Mycobacterial Lung Disease Is Complex; Thus, Shared Decision Making Is Critical.

作者信息

Marmor Meghan, Talbot Elizabeth A, Cohen Keira A

机构信息

Division of Pulmonary, Allergy and Critical Care, School of Medicine, Stanford University, Stanford, California.

Dartmouth-Hitchcock Medical Center, Geisel School of Medicine, Dartmouth University, Lebanon, New Hampshire; and.

出版信息

Ann Am Thorac Soc. 2022 Aug;19(8):1265-1267. doi: 10.1513/AnnalsATS.202201-002VP.

DOI:10.1513/AnnalsATS.202201-002VP
PMID:35316167
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12039943/
Abstract
摘要

相似文献

1
Treatment of Nontuberculous Mycobacterial Lung Disease Is Complex; Thus, Shared Decision Making Is Critical.非结核分枝杆菌肺病的治疗很复杂；因此，共同决策至关重要。
Ann Am Thorac Soc. 2022 Aug;19(8):1265-1267. doi: 10.1513/AnnalsATS.202201-002VP.
2
Medical Management of Pulmonary Nontuberculous Mycobacterial Disease.非结核分枝杆菌肺病的医学管理
Thorac Surg Clin. 2019 Feb;29(1):65-76. doi: 10.1016/j.thorsurg.2018.09.001.
3
Diagnostic Criteria and the Decision to Treat Nontuberculous Mycobacterial Pulmonary Disease.非结核分枝杆菌肺病的诊断标准和治疗决策。
Clin Chest Med. 2023 Dec;44(4):757-769. doi: 10.1016/j.ccm.2023.07.003. Epub 2023 Sep 1.
4
Treatment of the Less Common Nontuberculous Mycobacterial Pulmonary Disease.治疗少见非结核分枝杆菌肺病。
Clin Chest Med. 2023 Dec;44(4):799-813. doi: 10.1016/j.ccm.2023.06.011. Epub 2023 Aug 14.
5
What is new in BTS 2017 & ATS/ERS/ESCMID/IDSA 2020 guidelines on treatment of non-tuberculous mycobacterial pulmonary disease?英国胸科学会（BTS）2017年指南以及美国胸科学会（ATS）/欧洲呼吸学会（ERS）/欧洲临床微生物学与传染病学会（ESCMID）/美国感染病学会（IDSA）2020年非结核分枝杆菌肺病治疗指南中有哪些新内容？
Indian J Med Res. 2021 Mar;154(3):405-409. doi: 10.4103/ijmr.ijmr_2573_21.
6
Antibiotic treatment for nontuberculous mycobacterial lung disease.非结核分枝杆菌肺病的抗生素治疗
Expert Rev Respir Med. 2016;10(5):557-68. doi: 10.1586/17476348.2016.1165611. Epub 2016 Mar 30.
7
[Interpretation of clinical practice guideline on the treatment of nontuberculous mycobacterial pulmonary disease: Euro‑American 2020 edition].[非结核分枝杆菌肺病治疗临床实践指南解读：欧美2020版]
Zhonghua Jie He He Hu Xi Za Zhi. 2021 Aug 12;44(8):699-704. doi: 10.3760/cma.j.cn112147-20210222-00115.
8
Time to Consider Treatment Initiation for Patients With Nontuberculous Mycobacterial Lung Disease.非结核分枝杆菌肺病患者开始治疗的时机
Chest. 2022 Oct;162(4):e203-e204. doi: 10.1016/j.chest.2022.06.027.
9
A narrative review of nontuberculous mycobacterial pulmonary disease: microbiology, epidemiology, diagnosis, and management challenges.非结核分枝杆菌肺病的叙述性综述：微生物学、流行病学、诊断和管理挑战。
Expert Rev Respir Med. 2023 Jul-Dec;17(11):973-988. doi: 10.1080/17476348.2023.2283135. Epub 2023 Dec 26.
10
Recent advances in nontuberculous mycobacterial lung infections.非结核分枝杆菌肺部感染的最新进展
F1000Res. 2019 Oct 1;8. doi: 10.12688/f1000research.20096.1. eCollection 2019.

引用本文的文献

1
Comprehensive Management Algorithm for Complex Pulmonary Disease in the Real-World Setting.真实世界中复杂肺部疾病的综合管理算法
Ann Am Thorac Soc. 2025 May;22(5):651-659. doi: 10.1513/AnnalsATS.202408-904FR.
2
Usefulness of the BACES score in nontuberculous mycobacterial pulmonary disease for various clinical outcomes.BACES 评分在非结核分枝杆菌肺病各种临床结局中的应用。
Sci Rep. 2023 May 9;13(1):7495. doi: 10.1038/s41598-023-33782-z.

本文引用的文献

1
Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.非结核分枝杆菌肺病治疗：美国胸科学会/欧洲呼吸学会/欧洲临床微生物学和传染病学会/美国感染病学会临床实践指南。
Clin Infect Dis. 2020 Aug 14;71(4):905-913. doi: 10.1093/cid/ciaa1125.
2
BACES Score for Predicting Mortality in Nontuberculous Mycobacterial Pulmonary Disease.BACES 评分预测非结核分枝杆菌性肺病患者的死亡率。
Am J Respir Crit Care Med. 2021 Jan 15;203(2):230-236. doi: 10.1164/rccm.202004-1418OC.
3
What Exactly Is Shared Decision-Making? A Qualitative Study of Shared Decision-Making in Lung Cancer Screening.共享决策究竟是什么？一项关于肺癌筛查中共享决策的定性研究。
J Gen Intern Med. 2020 Feb;35(2):546-553. doi: 10.1007/s11606-019-05516-3. Epub 2019 Nov 19.
4
Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15-year follow-up study.1445例非结核分枝杆菌肺病患者长期死亡率的预后因素：一项15年随访研究
Eur Respir J. 2020 Jan 2;55(1). doi: 10.1183/13993003.00798-2019. Print 2020 Jan.
5
Retrospective evaluation of natural course in mild cases of Mycobacterium avium complex pulmonary disease.回顾性评估非结核分枝杆菌肺病轻症患者的自然病程。
PLoS One. 2019 Apr 25;14(4):e0216034. doi: 10.1371/journal.pone.0216034. eCollection 2019.
6
High mortality in patients with Mycobacterium avium complex lung disease: a systematic review.鸟分枝杆菌复合体肺病患者死亡率高：系统评价。
BMC Infect Dis. 2018 May 3;18(1):206. doi: 10.1186/s12879-018-3113-x.
7
Outcomes of complex lung disease based on clinical phenotype.基于临床表型的复杂肺部疾病的结局。
Eur Respir J. 2017 Sep 27;50(3). doi: 10.1183/13993003.02503-2016. Print 2017 Sep.
8
Factors which influence treatment initiation for pulmonary non-tuberculous mycobacterium infection in HIV negative patients; a multicentre observational study.影响HIV阴性患者非结核分枝杆菌肺部感染治疗起始的因素；一项多中心观察性研究。
Respir Med. 2016 Nov;120:101-108. doi: 10.1016/j.rmed.2016.10.001. Epub 2016 Oct 6.
9
Health-related quality of life is inversely correlated with C-reactive protein and age in Mycobacterium avium complex lung disease: a cross-sectional analysis of 235 patients.鸟分枝杆菌复合群肺病患者的健康相关生活质量与C反应蛋白及年龄呈负相关：对235例患者的横断面分析
Respir Res. 2015 Dec 3;16:145. doi: 10.1186/s12931-015-0304-5.
10
Using the Health Literacy Universal Precautions Toolkit to Improve the Quality of Patient Materials.使用健康素养通用预防措施工具包提高患者资料质量。
J Health Commun. 2015;20 Suppl 2(Suppl 2):69-76. doi: 10.1080/10810730.2015.1081997.